Business Context and Reporting Period
Company: Bone Biologics Corp (BBLG)
Filing Type: Form 8-K (Current Report)
Date of Report: September 10, 2026
Reporting Period: Event date September 10, 2026; Signed September 16, 2026
Business Context: The Company is a Delaware corporation with principal executive offices in Burlington, MA. Its common stock and warrants trade on the Nasdaq Capital Market.
Key Financial Metrics
This filing is a notice of a listing deficiency and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Listing Deficiency: The Company received notice from Nasdaq that it failed to meet Listing Rule 5550(a)(2) regarding the minimum bid price requirement of $1.00 per share.
- Trigger Event: The closing bid price of the Company's common stock remained below $1.00 for the last 30 consecutive business days prior to September 10, 2026.
- Compliance Status: The Company has been granted an initial 180-day compliance period ending March 9, 2027, to regain compliance.
Guidance, Outlook, and Risks
- Management Action Plan: The Company intends to seek stockholder approval for a reverse stock split at its upcoming annual meeting to increase the per-share price and regain compliance.
- Compliance Path: To regain compliance within the initial period, the Company must evidence a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.
- Delisting Risk: If the Company fails to regain compliance by March 9, 2027, it may be eligible for a second 180-day compliance period if it meets other listing standards. Failure to comply ultimately results in delisting.
- Forward-Looking Statements: The Company notes that actual results may differ materially from expectations, specifically regarding the ability to regain compliance and maintain Nasdaq listing.
Investor Verification Checklist
- Verify the current closing bid price of BBLG common stock to assess proximity to the $1.00 threshold.
- Confirm the date of the upcoming annual meeting of stockholders to determine the timeline for the reverse stock split proposal.
- Review the Company's most recent Form 10-K for detailed risk factors and financial health context not included in this 8-K.
- Monitor Nasdaq announcements for any updates regarding the Company's compliance status or potential second compliance period eligibility.